⚡ This is your brand? Claim your page FREE and bring it to life on AI search.

XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment

XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment

Unclaimed

AEO Score: 4/10

Monitoring for AI engine activity

In the Engagemii AEO index

xalkori.com

Share

What this score means

Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment just got measured.

4/10 means XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.

About XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment

Learn about Rx XALKORI® (crizotinib) for treatment of ALK+ or ROS1+ non-small cell lung cancer that has spread to other parts of the body. See risks & benefits.

Key Topics

If you have ALK+ or ROS1+ metastatic NSCLC,we can help guide your journey.
If you have ALK+ or ROS1+ metastatic NSCLC,we can help guide your journey.

Details

Industry: Healthcare

xalkori.com

AI Visibility Breakdown

1

Structured Data

6

Content Structure

6

Entity Clarity

4

E-E-A-T Signals

6

Technical AEO

2

AI Discoverability

Is this your brand?

Claim free. You'll see:

Your full 6-category score breakdown

Exact fixes: robots.txt, schema, llms.txt

AI bot crawls from ChatGPT, Claude, Perplexity, Gemini

Personal 50% off code at checkout

Already have an account? Sign in

Picked for XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment: Health & Wellness

Trust Is the Product. AI Is How You Build It at Scale.

In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.

Continue reading in your free Engagemii portal

Free signup unlocks the full article plus your personalized AEO fix list for XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment.

Source & Attribution

Scored by Engagemii on June 30, 2026. Methodology: engagemii.com/aeo/methodology

Source URL: https://engagemii.com/aeo/brands/xalkori

Cite this score: Engagemii (2026). "AEO Score for XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment." Retrieved from https://engagemii.com/aeo/brands/xalkori

Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.

Powered by Engagemii - AI Brand Discovery and AEO Platform